In J&J's psoriatic arthritis study, a pill cleared or nearly cleared skin in 57% of patients with skin involvement.

Johnson & Johnson (JNJ) reported that Icotyde, a therapy co-marketed with Protagonist Therapeutics (PTGX), showed success in a late-stage trial for psoriatic arthritis, according to the company. The drug is already FDA-approved for plaque psoriasis. Up to 30% of plaque psoriasis patients also develop psoriatic arthritis, per studies.

Johnson & Johnson (JNJ) presented Phase 2 data on nipocalimab for Sjögren’s disease, showing high patient satisfaction and symptom improvement. The drug demonstrated a 50%+ improvement in salivary flow vs. placebo. JNJ is conducting Phase 3 trials, with FDA designations for fast-track development.

Johnson & Johnson reported that its once-daily pill, Icotyde, showed significant improvement in psoriatic arthritis symptoms in a late-stage trial. 58% of patients taking Icotyde saw a 20% improvement in joint counts and disease activity, compared to 41% on placebo. The drug is already FDA-approved for psoriasis and could expand into psoriatic arthritis, with peak sales expected to exceed $5 billion.

Johnson & Johnson (JNJ) presented new Phase 2 data on nipocalimab for Sjögren's disease, showing mouth dryness as the most critical symptom for patients. The study found a 50% increase in saliva production in more patients treated with nipocalimab compared to placebo. Two Phase 3 studies are ongoing, focusing on patient-valued outcomes. Nipocalimab has received Breakthrough Therapy and Fast Track Designations from the FDA for this indication.

Johnson & Johnson (JNJ) reported positive Phase 3 trial results for ICOTYDE (icotrokinra) in treating psoriatic arthritis. 58% of patients achieved ACR20 response vs. 41% on placebo. The drug showed joint and skin improvements with a favorable safety profile. Results were presented at the ACR Convergence 2026.

Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) received FDA accelerated approval for recurrent or metastatic head and neck cancer, excluding HPV-associated cases. The approval was based on a 42% objective response rate in the OrigAMI-4 trial, double the rate of prior therapies. The drug targets EGFR and MET, with common side effects including rash and fatigue. According to Johnson & Johnson, this approval offers new hope for patients with limited treatment options.